Sign in

CIK 0001640266 · Accelerated filer<br>Smaller reporting company

Voyager Therapeutics, Inc.

Sign in to watch
Ticker
VYGR
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
operating
Phone
857-259-5340
Business address
75 HAYDEN AVENUE, LEXINGTON, MA, 02421
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$0
in 0 filings

Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Reading 100 more Form 4s from the SEC; this list fills in as they're read.

Date Insider Transaction Shares Price Value Owned after
2026-11-01 Carter Todd Alfred Chief Scientific Officer Grant or award +33,000 178,718
2026-11-01 Carter Todd Alfred Chief Scientific Officer Grant or award · Stock Option (Right to Buy) +154,000 154,000
2026-11-01 Swartz Robin President Grant or award +68,250 267,988
2026-11-01 Swartz Robin President Grant or award · Stock Option (Right to Buy) +318,500 318,500
2026-06-09 SCANGOS GEORGE A Director Grant or award · Stock Option (Right to Buy) +30,000 30,000
2026-06-09 MACKEY CATHERINE J Director Grant or award · Stock Option (Right to Buy) +30,000 30,000
2026-06-09 Hyman Steven Director Grant or award · Stock Option (Right to Buy) +30,000
2026-06-09 Vitale Nancy Director Grant or award · Stock Option (Right to Buy) +30,000 30,000
2026-06-09 Higgins Michael J Director Grant or award · Stock Option (Right to Buy) +30,000 30,000
2026-06-09 Onyia Jude Director Grant or award · Stock Option (Right to Buy) +30,000 30,000
2026-06-09 GERAGHTY JAMES A Director Grant or award · Stock Option (Right to Buy) +30,000 30,000
2026-06-09 Colon Grace Director Grant or award · Stock Option (Right to Buy) +30,000
2026-06-09 PIERCE GLENN Director Grant or award · Stock Option (Right to Buy) +30,000 30,000
2026-04-02 Sandrock Alfred President and CEO Sale 10b5-1 −11,511 $3.87 $45K 472,549
2026-04-01 Shiferman Gregory L. SVP and General Counsel Grant or award +50,000 50,000
2026-02-24 Swartz Robin COO & CBO Sale 10b5-1 −6,458 $3.77 $24K 199,738
2026-02-24 Sandrock Alfred President and CEO Sale 10b5-1 −14,197 $3.79 $54K 484,060
2026-02-24 Jorgensen Nathan D. Chief Financial Officer Sale 10b5-1 −4,668 $3.77 $18K 151,416
2026-02-24 Carter Todd Alfred Chief Scientific Officer Sale 10b5-1 −4,174 $3.76 $16K 145,718
2026-02-18 Swartz Robin COO & CBO Sale 10b5-1 −3,882 $3.44 $13K 206,196

Page 1 of 7 · 130 trades